Lilly Announces Strategic Changes to its Global Manufacturing Operations

March 2007
BioPharm International;Mar2007, Vol. 20 Issue 3, p18
Trade Publication
The article announces the strategic changes of Eli Lilly and Co. on its global manufacturing operations. The changes were made to better support the company's product portfolio and evolving drug pipeline. The construction of the planned insulin manufacturing plant located in Prince William County will be stopped because the company can already meet the expected growth in insulin demand with its existing sites and insulin capacity being built in Italy.


Related Articles

  • Lilly set to blossom in UK. Gordon, Michael // European Chemical News;6/9/2003, Vol. 78 Issue 2056, p27 

    Deals the investment plans of pharmaceutical manufacturer Eli Lilly in Great Britain through 2007. Scope of the investment strategy of Eli Lilly.

  • Aftermath of the Matrix Mania. Pitts, Robert A.; Daniels, John D. // Columbia Journal of World Business;Summer84, Vol. 19 Issue 2, p48 

    The article focuses on the role of reporting type of structure referred to as a matrix in the changes in the organizational structures. In a research sample it was found that single line reporting structures are still very much the norms in the U.S. multinational enterprises (MNEs).It has been...

  • Competitive Landscape.  // U.S. Pharma & Healthcare Report;Q2 2008, p77 

    The article provides an overview of the pharmaceutical market in the U.S. It is noted that all large and most medium sized multinational drug companies have a presence on the U.S. market, including research & development (R&D) sites, manufacturing plants and marketing divisions. Pfizer is said...

  • Eli Lilly Co. to enter companion-animal market segment.  // DVM: The Newsmagazine of Veterinary Medicine;Feb2007, Vol. 38 Issue 2, p60 

    The article reports on the move of Eli Lilly Co. to enter into the companion-animal segment by giving $250,000 endowment to the Center for the Human-Animal Bond at Purdue University School of Veterinary Medicine. The endowment aimed at supporting veterinarians understanding of physiological,...

  • Generic Batch Procedures for Flexible Manufacturing. Wood, Aaron // Control Engineering;Mar2009, Vol. 56 Issue 3, pP1 

    The article discusses Eli Lilly & Company's bulk pharmaceutical production buildings transformation into a facility that can also accommodate single-development product campaigns. A project team was reportedly assembled to formulate a strategy for implementing flexible control for the...

  • Eli Lilly LLY. Conover, Damien // Morningstar StockInvestor;8/15/2009, Vol. 9 Issue 2, p9 

    The article presents a corporate profile of pharmaceutical company Eli Lilly & Co. in the U.S. The company has manufactured antipsychotic drugs like Zyprexa, Cymbalta, Gemzar and other therapeutic products in neuroscience, endocrinology, oncology and cardiovascular disorder. It is stated that...

  • LILLY'S TERIPARATIDE GETS POSITIVE OPINION FROM CPMP.  // Worldwide Biotech;Feb2003, Vol. 15 Issue 2, p8 

    Reports on the positive opinion issued by the European Committee for Proprietary Medicinal Products concerning the teriparatide (rDNA origin) injection from Lilly.

  • Eli Lilly and Co.  // Indianapolis Business Journal;3/24/2003, Vol. 24 Issue 2, p35 

    Features Eli Lilly and Co., an Indianapolis, Indiana-based pharmaceutical company. Stock value; Major shareholders; Executive compensation; Corporate directors.

  • Lilly looms larger. Jefferson, Greg // Indianapolis Business Journal;07/19/99, Vol. 20 Issue 18, p1A 

    Reports on Indianapolis, Indiana-based drug firm Eli Lilly's expansion plan in Indiana. Company profile; Effect on the cultural and economic makeup of Indiana; Pledge of investments for construction and renovation projects; Projects; Addition of employees. INSET: In first speech to Indy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics